CSBio CSBio

X
[{"orgOrder":0,"company":"Sanofi","sponsor":"Global Blood Therapeutics","pharmaFlowCategory":"D","amount":"$353.0 million","upfrontCash":"Undisclosed","newsHeadline":"GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sanofi"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            These mechanisms of the two licensed novel small moleculeare are distinct and potentially complementary to that of Oxbryta tablets, a novel hemoglobin S polymerization inhibitor approved in the United States for the treatment of SCD in patients ages 12 years and older.

            Lead Product(s): Undisclosed

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Global Blood Therapeutics

            Deal Size: $353.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement March 16, 2021

            Sanofi Company Banner

            TMF Summit 2024

            Not Confirmed

            envelop Contact Supplier
            Post Enquiry
            POST ENQUIRY